Validation of the French Version of the MacArthur Competence Assessment Tool for Treatment (MacCAT-T) in a French Sample of Individuals with Schizophrenia: Validation de la version française de l'instrument d'évaluation des compétences MacArthur-traitement (MacCAT-T) dans un échantillon français de personnes souffrant de schizophrénie.

MacArthur Competence Assessment Tool for Treatment insight schizophrenia treatment decision-making capacity

Journal

Canadian journal of psychiatry. Revue canadienne de psychiatrie
ISSN: 1497-0015
Titre abrégé: Can J Psychiatry
Pays: United States
ID NLM: 7904187

Informations de publication

Date de publication:
04 2021
Historique:
pubmed: 17 10 2020
medline: 19 8 2021
entrez: 16 10 2020
Statut: ppublish

Résumé

Assessing an individual's capacity to consent to treatment is a complex and challenging task for psychiatrists and health-care professionals. Diminished capacity to consent to pharmacological treatment is a common concern in individuals with schizophrenia. The MacArthur Competence Assessment Tool for Treatment (MacCAT-T) is the most common tool used in individuals with schizophrenia to evaluate the decision-making abilities for judgments about competence to consent to treatment. This instrument assesses patients' competence to make treatment decisions by examining their capacities in 4 areas: understanding information relevant to their condition and the recommended treatment, reasoning about the potential risks and benefits of their choices, appreciating the nature of their situation and the consequences of their choices, and expressing a choice. Despite its importance, there is no French version of this scale. Furthermore, its factor structure has never been explored, although validated measures are strongly needed to further detect deficits in patients' decision-making abilities. The goal of this study was thus to empirically validate a French version of the MacCAT-T in a French sample of individuals with schizophrenia. In this cross-sectional study, we included 125 inpatients with a diagnosis of schizophrenia from the University Department of Adult Psychiatry in Montpellier. The MacCAT-T was administered to patients by a trained psychologist. Patients were also assessed for severity of symptoms, insight into illness, and depressive and anxiety symptoms. Inter-rater reliability and psychometric properties including internal consistency, construct validity, and discriminant and divergent validity were also investigated. The MacCAT-T's internal consistency was high (Cronbach α of 0.91). A high degree of inter-rater reliability was found for all the areas of the MacCAT-T (intraclass correlation coefficient range, 0.92 to 0.98). Exploratory factor analysis revealed a 2-factor model. The factor analysis explained 50.03% of the total score variation. Component 1 included all subparts of "understanding." Component 2 included all subparts of "appreciation" and "reasoning" and was therefore labeled "reflexivity." After Bonferroni corrections, decision-making capacity was positively associated with insight and the severity of psychotic symptoms but not with sociodemographic variables except for education. The MacCAT-T demonstrated a high degree of inter-rater reliability and strong psychometric properties. The French version of the MacCAT-T is a valid instrument to assess the decision-making capacity to consent to treatment in a French sample of individuals with schizophrenia.

Sections du résumé

BACKGROUND
Assessing an individual's capacity to consent to treatment is a complex and challenging task for psychiatrists and health-care professionals. Diminished capacity to consent to pharmacological treatment is a common concern in individuals with schizophrenia. The MacArthur Competence Assessment Tool for Treatment (MacCAT-T) is the most common tool used in individuals with schizophrenia to evaluate the decision-making abilities for judgments about competence to consent to treatment. This instrument assesses patients' competence to make treatment decisions by examining their capacities in 4 areas: understanding information relevant to their condition and the recommended treatment, reasoning about the potential risks and benefits of their choices, appreciating the nature of their situation and the consequences of their choices, and expressing a choice. Despite its importance, there is no French version of this scale. Furthermore, its factor structure has never been explored, although validated measures are strongly needed to further detect deficits in patients' decision-making abilities. The goal of this study was thus to empirically validate a French version of the MacCAT-T in a French sample of individuals with schizophrenia.
METHOD
In this cross-sectional study, we included 125 inpatients with a diagnosis of schizophrenia from the University Department of Adult Psychiatry in Montpellier. The MacCAT-T was administered to patients by a trained psychologist. Patients were also assessed for severity of symptoms, insight into illness, and depressive and anxiety symptoms. Inter-rater reliability and psychometric properties including internal consistency, construct validity, and discriminant and divergent validity were also investigated.
RESULTS
The MacCAT-T's internal consistency was high (Cronbach α of 0.91). A high degree of inter-rater reliability was found for all the areas of the MacCAT-T (intraclass correlation coefficient range, 0.92 to 0.98). Exploratory factor analysis revealed a 2-factor model. The factor analysis explained 50.03% of the total score variation. Component 1 included all subparts of "understanding." Component 2 included all subparts of "appreciation" and "reasoning" and was therefore labeled "reflexivity." After Bonferroni corrections, decision-making capacity was positively associated with insight and the severity of psychotic symptoms but not with sociodemographic variables except for education.
CONCLUSIONS
The MacCAT-T demonstrated a high degree of inter-rater reliability and strong psychometric properties. The French version of the MacCAT-T is a valid instrument to assess the decision-making capacity to consent to treatment in a French sample of individuals with schizophrenia.

Identifiants

pubmed: 33064578
doi: 10.1177/0706743720966443
pmc: PMC8172341
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

395-405

Références

Rev Calid Asist. 2012 Mar-Apr;27(2):85-91
pubmed: 22115930
Br J Psychiatry. 2012 Aug;201:83-4
pubmed: 22859572
Br J Psychiatry. 2013 Dec;203(6):461-7
pubmed: 23969482
Schizophr Res. 2013 Mar;144(1-3):118-21
pubmed: 23313358
Arch Gen Psychiatry. 2000 Jun;57(6):533-8
pubmed: 10839330
Value Health. 2005 Mar-Apr;8(2):94-104
pubmed: 15804318
Br J Psychiatry. 1975 Mar;126:237-40
pubmed: 1125504
Schizophr Res. 2017 May;183:56-63
pubmed: 27876273
Am J Psychiatry. 1999 Sep;156(9):1380-4
pubmed: 10484948
Psychiatry Res. 2013 Dec 15;210(2):634-40
pubmed: 23928212
Am J Geriatr Psychiatry. 2009 May;17(5):428-36
pubmed: 19390300
N Engl J Med. 1988 Dec 22;319(25):1635-8
pubmed: 3200278
Br J Psychiatry. 2009 Sep;195(3):257-63
pubmed: 19721117
Arch Gen Psychiatry. 2004 Mar;61(3):230-6
pubmed: 14993110
Curr Neurol Neurosci Rep. 2010 Sep;10(5):367-73
pubmed: 20549394
Psychol Med. 2017 Aug;47(11):1906-1922
pubmed: 28441976
Am J Psychiatry. 2006 Aug;163(8):1323-34
pubmed: 16877642
Int J Law Psychiatry. 2018 May - Jun;58:27-35
pubmed: 29853010
Can J Psychiatry. 2010 Aug;55(8):523-31
pubmed: 20723280
Neurology. 2014 Aug 5;83(6):537-41
pubmed: 24991034
J R Soc Med. 2004 Sep;97(9):415-20
pubmed: 15340019
Br J Psychiatry. 2007 Oct;191:291-7
pubmed: 17906238
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Psychiatr Q. 1993 Winter;64(4):305-18
pubmed: 8234544
Law Hum Behav. 1995 Apr;19(2):127-48
pubmed: 11660291
Psychiatr Serv. 1998 Sep;49(9):1193-6
pubmed: 9735961
Ann Gen Psychiatry. 2013 Apr 09;12(1):10
pubmed: 23570333
Schizophr Res. 2004 Jun 1;68(2-3):319-29
pubmed: 15099613
Aust N Z J Psychiatry. 2018 Sep;52(9):826-833
pubmed: 29952217
Psychiatr Serv. 1997 Nov;48(11):1415-9
pubmed: 9355168
Am J Psychiatry. 2005 Jun;162(6):1209-11
pubmed: 15930073
Schizophr Res. 2008 Feb;99(1-3):350-8
pubmed: 18164593
J Clin Psychiatry. 2015 Aug;76(8):1068-74; quiz 1074
pubmed: 26335084
Schizophr Res. 2009 Mar;108(1-3):272-9
pubmed: 19162443
Br J Psychiatry. 2005 Oct;187:379-85
pubmed: 16199799
Can J Psychiatry. 1980 Feb;25(1):78-85
pubmed: 7370901

Auteurs

Stéphane Raffard (S)

University Department of Adult Psychiatry, 26905CHU Montpellier, University Montpellier 1, Hôpital la Colombière, France.
27038Université Paul Valéry Montpellier 3, EPSYLON EA, France.

Cindy Lebrun (C)

27038Université Paul Valéry Montpellier 3, EPSYLON EA, France.

Yasmine Laraki (Y)

University Department of Adult Psychiatry, 26905CHU Montpellier, University Montpellier 1, Hôpital la Colombière, France.
27038Université Paul Valéry Montpellier 3, EPSYLON EA, France.

Delphine Capdevielle (D)

University Department of Adult Psychiatry, 26905CHU Montpellier, University Montpellier 1, Hôpital la Colombière, France.
Inserm, Neuropsychiatry: Epidemiological and Clinical Research, University of Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH